vs
MESA LABORATORIES INC（MLAB）与Repay Holdings Corp（RPAY）财务数据对比。点击上方公司名可切换其他公司
Repay Holdings Corp的季度营收约是MESA LABORATORIES INC的1.2倍（$78.6M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs -178.3%，领先183.9%），MESA LABORATORIES INC同比增速更快（3.6% vs 0.4%），Repay Holdings Corp自由现金流更多（$23.2M vs $18.0M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -1.3%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
Repay Holdings Corp是一家聚焦北美市场的支付技术服务商，为零售、医疗、汽车服务、电商等领域的企业提供整合支付处理方案，涵盖银行卡收单、ACH转账、POS系统集成等数字化支付工具，助力客户简化交易流程、提升运营效率。
MLAB vs RPAY — 直观对比
营收规模更大
RPAY
是对方的1.2倍
$65.1M
营收增速更快
MLAB
高出3.2%
0.4%
净利率更高
MLAB
高出183.9%
-178.3%
自由现金流更多
RPAY
多$5.2M
$18.0M
两年增速更快
MLAB
近两年复合增速
-1.3%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $78.6M |
| 净利润 | $3.6M | $-140.1M |
| 毛利率 | 64.2% | 74.2% |
| 营业利润率 | 12.2% | -182.2% |
| 净利率 | 5.6% | -178.3% |
| 营收同比 | 3.6% | 0.4% |
| 净利润同比 | 316.6% | -3304.1% |
| 每股收益（稀释后） | $0.65 | $-1.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABRPAY
| Q4 25 | $65.1M | $78.6M | ||
| Q3 25 | $60.7M | $77.7M | ||
| Q2 25 | $59.5M | $75.6M | ||
| Q1 25 | $62.1M | $77.3M | ||
| Q4 24 | $62.8M | $78.3M | ||
| Q3 24 | $57.8M | $79.1M | ||
| Q2 24 | $58.2M | $74.9M | ||
| Q1 24 | $58.9M | $80.7M |
净利润MLABRPAY
| Q4 25 | $3.6M | $-140.1M | ||
| Q3 25 | $2.5M | $-6.4M | ||
| Q2 25 | $4.7M | $-102.3M | ||
| Q1 25 | $-7.1M | $-7.9M | ||
| Q4 24 | $-1.7M | $-4.1M | ||
| Q3 24 | $3.4M | $3.2M | ||
| Q2 24 | $3.4M | $-4.1M | ||
| Q1 24 | $-254.6M | $-5.2M |
毛利率MLABRPAY
| Q4 25 | 64.2% | 74.2% | ||
| Q3 25 | 61.5% | 74.4% | ||
| Q2 25 | 62.0% | 75.7% | ||
| Q1 25 | 61.8% | 75.9% | ||
| Q4 24 | 63.3% | 76.3% | ||
| Q3 24 | 61.3% | 77.8% | ||
| Q2 24 | 64.0% | 78.2% | ||
| Q1 24 | 62.1% | 76.2% |
营业利润率MLABRPAY
| Q4 25 | 12.2% | -182.2% | ||
| Q3 25 | 7.8% | -3.9% | ||
| Q2 25 | 5.1% | -138.7% | ||
| Q1 25 | 2.4% | -4.7% | ||
| Q4 24 | 9.2% | -1.5% | ||
| Q3 24 | 6.1% | -0.9% | ||
| Q2 24 | 9.6% | -4.6% | ||
| Q1 24 | -460.6% | -3.1% |
净利率MLABRPAY
| Q4 25 | 5.6% | -178.3% | ||
| Q3 25 | 4.1% | -8.3% | ||
| Q2 25 | 8.0% | -135.2% | ||
| Q1 25 | -11.4% | -10.3% | ||
| Q4 24 | -2.7% | -5.3% | ||
| Q3 24 | 5.9% | 4.1% | ||
| Q2 24 | 5.8% | -5.4% | ||
| Q1 24 | -432.2% | -6.5% |
每股收益（稀释后）MLABRPAY
| Q4 25 | $0.65 | $-1.68 | ||
| Q3 25 | $0.45 | $-0.08 | ||
| Q2 25 | $0.85 | $-1.15 | ||
| Q1 25 | $-1.30 | $-0.09 | ||
| Q4 24 | $-0.31 | $-0.04 | ||
| Q3 24 | $0.63 | $0.03 | ||
| Q2 24 | $0.62 | $-0.04 | ||
| Q1 24 | $-47.26 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $115.7M |
| 总债务越低越好 | $68.4M | $280.1M |
| 股东权益账面价值 | $186.7M | $484.4M |
| 总资产 | $434.8M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.37× | 0.58× |
8季度趋势，按日历期对齐
现金及短期投资MLABRPAY
| Q4 25 | $29.0M | $115.7M | ||
| Q3 25 | $20.4M | $95.7M | ||
| Q2 25 | $21.3M | $162.6M | ||
| Q1 25 | $27.3M | $165.5M | ||
| Q4 24 | $27.3M | $189.5M | ||
| Q3 24 | $24.3M | $168.7M | ||
| Q2 24 | $28.5M | $147.1M | ||
| Q1 24 | $28.2M | $128.3M |
总债务MLABRPAY
| Q4 25 | $68.4M | $280.1M | ||
| Q3 25 | $69.4M | $279.5M | ||
| Q2 25 | $70.3M | $279.0M | ||
| Q1 25 | $71.3M | $497.6M | ||
| Q4 24 | $72.2M | $496.8M | ||
| Q3 24 | $73.1M | $496.2M | ||
| Q2 24 | $74.1M | $435.6M | ||
| Q1 24 | — | $434.9M |
股东权益MLABRPAY
| Q4 25 | $186.7M | $484.4M | ||
| Q3 25 | $178.5M | $616.9M | ||
| Q2 25 | $172.5M | $633.7M | ||
| Q1 25 | $159.8M | $755.7M | ||
| Q4 24 | $155.2M | $761.3M | ||
| Q3 24 | $161.5M | $754.7M | ||
| Q2 24 | $150.7M | $815.4M | ||
| Q1 24 | $145.4M | $813.8M |
总资产MLABRPAY
| Q4 25 | $434.8M | $1.2B | ||
| Q3 25 | $430.4M | $1.3B | ||
| Q2 25 | $435.7M | $1.4B | ||
| Q1 25 | $433.3M | $1.5B | ||
| Q4 24 | $433.3M | $1.6B | ||
| Q3 24 | $454.1M | $1.6B | ||
| Q2 24 | $440.4M | $1.5B | ||
| Q1 24 | $446.8M | $1.5B |
负债/权益比MLABRPAY
| Q4 25 | 0.37× | 0.58× | ||
| Q3 25 | 0.39× | 0.45× | ||
| Q2 25 | 0.41× | 0.44× | ||
| Q1 25 | 0.45× | 0.66× | ||
| Q4 24 | 0.47× | 0.65× | ||
| Q3 24 | 0.45× | 0.66× | ||
| Q2 24 | 0.49× | 0.53× | ||
| Q1 24 | — | 0.53× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $23.3M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $23.2M |
| 自由现金流率自由现金流/营收 | 27.7% | 29.6% |
| 资本支出强度资本支出/营收 | 1.1% | 0.1% |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | $90.7M |
8季度趋势，按日历期对齐
经营现金流MLABRPAY
| Q4 25 | $18.8M | $23.3M | ||
| Q3 25 | $8.2M | $32.2M | ||
| Q2 25 | $1.9M | $33.1M | ||
| Q1 25 | $12.7M | $2.5M | ||
| Q4 24 | $18.1M | $34.3M | ||
| Q3 24 | $5.3M | $60.1M | ||
| Q2 24 | $10.7M | $31.0M | ||
| Q1 24 | $12.9M | $24.8M |
自由现金流MLABRPAY
| Q4 25 | $18.0M | $23.2M | ||
| Q3 25 | $7.1M | $32.1M | ||
| Q2 25 | $884.0K | $33.0M | ||
| Q1 25 | $11.9M | $2.4M | ||
| Q4 24 | $17.3M | $34.0M | ||
| Q3 24 | $3.5M | $59.8M | ||
| Q2 24 | $9.9M | $30.5M | ||
| Q1 24 | $12.3M | $24.7M |
自由现金流率MLABRPAY
| Q4 25 | 27.7% | 29.6% | ||
| Q3 25 | 11.7% | 41.3% | ||
| Q2 25 | 1.5% | 43.6% | ||
| Q1 25 | 19.2% | 3.0% | ||
| Q4 24 | 27.6% | 43.5% | ||
| Q3 24 | 6.0% | 75.6% | ||
| Q2 24 | 16.9% | 40.7% | ||
| Q1 24 | 21.0% | 30.6% |
资本支出强度MLABRPAY
| Q4 25 | 1.1% | 0.1% | ||
| Q3 25 | 1.8% | 0.2% | ||
| Q2 25 | 1.7% | 0.1% | ||
| Q1 25 | 1.2% | 0.2% | ||
| Q4 24 | 1.3% | 0.3% | ||
| Q3 24 | 3.1% | 0.3% | ||
| Q2 24 | 1.5% | 0.6% | ||
| Q1 24 | 0.9% | 0.1% |
现金转化率MLABRPAY
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | 18.52× | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
RPAY
| Sales Channel Directly To Consumer | $69.4M | 88% |
| Other | $6.8M | 9% |
| Sales Channel Through Intermediary | $2.3M | 3% |
